Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNSET: Surfactant Nebulization for Preterm Lung
NCT04315636Phase 3Completed
- Sponsor
- University of Zurich
- Start
- Mar 2021
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Poractant alfa in respiratory distress syndrome (RDS), sponsored by University of Zurich. Started Mar 2021; status: completed.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT04315636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315636.